Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS P.G12C”

156 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 156 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04625647
What this trial is testing

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Who this might be right for
Lung AdenocarcinomaLung Non-Small Cell CarcinomaRecurrent Lung Non-Squamous Non-Small Cell Carcinoma+3 more
SWOG Cancer Research Network 116
Testing effectiveness (Phase 2)Study completedNCT04933695
What this trial is testing

Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment

Who this might be right for
Non-small Cell Lung Cancer
Amgen 42
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07164170
What this trial is testing

Clinical Study of Combination Therapy With ABSK043 and Glecirasib

Who this might be right for
Non-Small Cell Lung Cancer
Abbisko Therapeutics Co, Ltd 86
Testing effectiveness (Phase 2)Active Not RecruitingNCT05074810
What this trial is testing

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Who this might be right for
Non Small Cell Lung CancerKRAS Activating Mutation
Verastem, Inc. 153
Early research (Phase 1)Looking for participantsNCT06383871
What this trial is testing

A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour

Who this might be right for
Advanced Malignant Tumour
Shandong Suncadia Medicine Co., Ltd. 233
Not applicableNo Longer AvailableNCT04667234
What this trial is testing

Expanded Access of Sotorasib

Who this might be right for
Non Small-cell Lung CancerLocally Advanced Unresectable NSCLCLocally Advanced Metastatic NSCLC
Amgen
Testing effectiveness (Phase 2)Active Not RecruitingNCT05009329
What this trial is testing

JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

Who this might be right for
NSCLCSolid Tumor
Allist Pharmaceuticals, Inc. 315
Large-scale testing (Phase 3)Looking for participantsNCT06119581
What this trial is testing

First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungNeoplasm Metastasis
Eli Lilly and Company 1,264
Early research (Phase 1)Looking for participantsNCT07094204
What this trial is testing

Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Who this might be right for
Solid TumorNon-Small-Cell Lung CancerPancreatic Ductal Adenocarcinoma+1 more
Astellas Pharma Inc 364
Early research (Phase 1)Active Not RecruitingNCT03260491
What this trial is testing

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Daiichi Sankyo 312
Early research (Phase 1)Study completedNCT05178888
What this trial is testing

Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)

Who this might be right for
Advanced Solid Tumor
Mirati Therapeutics Inc. 11
Early research (Phase 1)Looking for participantsNCT06659341
What this trial is testing

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

Who this might be right for
Advanced Solid Tumors Harboring KRAS G12C Mutation
Bayer 104
Testing effectiveness (Phase 2)Looking for participantsNCT06008288
What this trial is testing

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

Who this might be right for
KRAS P.G12CPancreatic CancerSolid Tumor
Allist Pharmaceuticals, Inc. 88
Large-scale testing (Phase 3)Looking for participantsNCT07431827
What this trial is testing

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 400
Testing effectiveness (Phase 2)Active Not RecruitingNCT05853575
What this trial is testing

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Who this might be right for
Advanced CancerMetastatic CancerMalignant Neoplasm of Lung
Mirati Therapeutics Inc. 200
Early research (Phase 1)Ended earlyNCT04975256
What this trial is testing

Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

Who this might be right for
Advanced CancerMetastatic CancerMalignant Neoplasm of Colon+2 more
Mirati Therapeutics Inc. 7
Early research (Phase 1)Ended earlyNCT06130254
What this trial is testing

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Who this might be right for
Advanced Solid TumorNon-small Cell Lung Cancers
M.D. Anderson Cancer Center 1
Early research (Phase 1)Active Not RecruitingNCT06235983
What this trial is testing

LY3537982 in Chinese Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Eli Lilly and Company 12
Testing effectiveness (Phase 2)WithdrawnNCT05180422
What this trial is testing

A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis

Who this might be right for
Non Small Cell Lung Cancer
Criterium, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT06248606
What this trial is testing

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

Who this might be right for
Non Small Cell Lung CancerNSCLCKRAS G12C
Ryan Gentzler, MD 30
Load More Results